Desman Jacob M, Hong Zhang-Wei, Sabounchi Moein, Sawant Ashwin S, Gill Jaskirat, Costa Ana C, Kumar Gagan, Sharma Rajeev, Gupta Arpeta, McCarthy Paul, Nandwani Veena, Powell Doug, Carideo Alexandra, Goodwin Donnie, Ahmed Sanam, Gidwani Umesh, Levin Matthew A, Varghese Robin, Filsoufi Farzan, Freeman Robert, Shetreat-Klein Avniel, Charney Alexander W, Hofer Ira, Chan Lili, Reich David, Kovatch Patricia, Kohli-Seth Roopa, Kraft Monica, Agrawal Pulkit, Kellum John A, Nadkarni Girish N, Sakhuja Ankit
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Division of Data-Driven and Digital Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
NPJ Digit Med. 2025 May 27;8(1):313. doi: 10.1038/s41746-025-01709-9.
This study introduces Glucose Level Understanding and Control Optimized for Safety and Efficacy (GLUCOSE), a distributional offline reinforcement learning algorithm for optimizing insulin dosing after cardiac surgery. Trained on 5228 patients, tested on 920, and externally validated on 649, GLUCOSE achieved a mean estimated reward of 0.0 [-0.07, 0.06] in internal testing and -0.63 [-0.74, -0.52] in external validation, outperforming clinician returns of -1.29 [-1.37, -1.20] and -1.02 [-1.16, -0.89]. In multi-phase human validation, GLUCOSE first showed a significantly lower mean absolute error (MAE) in insulin dosing, with 0.9 units MAE versus clinicians' 1.97 units (p < 0.001) in internal testing and 1.90 versus 2.24 units (p = 0.003) in external validation. The second and third phases found GLUCOSE's performance as comparable to or exceeding that of senior clinicians in MAE, safety, effectiveness, and acceptability. These findings suggest GLUCOSE as a robust tool for improving postoperative glucose management.
本研究介绍了葡萄糖水平理解与控制优化以确保安全性和有效性(GLUCOSE),这是一种用于优化心脏手术后胰岛素给药的分布式离线强化学习算法。GLUCOSE在5228例患者身上进行训练,在920例患者身上进行测试,并在649例患者身上进行外部验证,在内部测试中平均估计奖励为0.0[-0.07,0.06],在外部验证中为-0.63[-0.74,-0.52],优于临床医生的回报-1.29[-1.37,-1.20]和-1.02[-1.16,-0.89]。在多阶段人体验证中,GLUCOSE首先在胰岛素给药方面显示出显著更低的平均绝对误差(MAE),内部测试中MAE为0.9单位,而临床医生为1.97单位(p<0.001),外部验证中为1.90单位对2.24单位(p=0.003)。第二和第三阶段发现,GLUCOSE在MAE、安全性、有效性和可接受性方面的表现与资深临床医生相当或超过他们。这些发现表明GLUCOSE是改善术后血糖管理的有力工具。